Implications of noncoding RNAs for cancer therapy: Are we aiming at the right targets?

Amil Shah

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002286

PDF (1207KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002286 DOI: 10.37349/etat.2025.1002286
Perspective
research-article
Implications of noncoding RNAs for cancer therapy: Are we aiming at the right targets?
Author information +
History +
PDF (1207KB)

Abstract

The discovery of oncogenes and tumor suppressor genes led to a better understanding of tumorigenesis, and prompted the development of molecularly targeted therapy. Over the past 30 years, many new drugs, which are primarily aimed at activated oncogenic proteins in signal transduction pathways involved in cell proliferation and survival, have been introduced in the clinic. Despite its rational design, the overall efficacy of targeted therapy has been modest. Recently, the noncoding RNAs (ncRNAs) have emerged as key regulators of important cellular processes in addition to the known regulatory proteins. It now appears that dual epigenetic regulatory systems exist in higher eukaryotic cells: a ncRNA network that governs essential cell functions, like cell fate decision and maintenance of homeostasis, and a protein-based system that presides over core physiological processes, like cell division and genomic maintenance. Modifications of the ncRNA network due to altered ncRNAs can cause the cell to shift towards to neoplastic phenotype; this is cancer initiation. Mutations in the well-known cancer driver genes provide the incipient cancer cell with a selective growth advantage and fuel its consequent clonal expansion. Because of the crucial role of the altered ncRNAs in tumorigenesis, targeting them may be a reasonable therapeutic strategy.

Keywords

Tumorigenesis / noncoding RNA / RNA regulatory network / cancer initiation / targeted therapy / nucleic acid-based therapy

Cite this article

Download citation ▾
Amil Shah. Implications of noncoding RNAs for cancer therapy: Are we aiming at the right targets?. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002286 DOI:10.37349/etat.2025.1002286

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.

[2]

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013; 339: 1546-58.

[3]

Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022; 54: 1670-94.

[4]

Villacampa G, Navarro V, Matikas A, Ribeiro JM, Schettini F, Tolosa P, et al. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and MetaAnalysis. JAMA Oncol. 2024; 10: 1331-41.

[5]

Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of selfrenewing tissues originate prior to tumor initiation. Proc Natl Acad Sci U S A. 2013; 110: 1999-2004.

[6]

Adashek JJ, Kato S, Lippman SM, Kurzrock R. The paradox of cancer genes in nonmalignant conditions: implications for precision medicine. Genome Med. 2020; 12: 16.

[7]

ICGC/TCGA PanCancer Analysis of Whole Genomes Consortium. Pancancer analysis of whole genomes. Nature. 2020; 578: 82-93.

[8]

Bernards R, Weinberg RA. A progression puzzle. Nature. 2002; 418: 823.

[9]

de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer. 2004; 4: 769-80.

[10]

Shah A. Rethinking cancer initiation: The role of largescale mutational events. Genes Chromosomes Cancer. 2024; 63: e23213.

[11]

ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489: 57-74.

[12]

Nemeth K, Bayraktar R, Ferracin M, Calin GA. Noncoding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet. 2024; 25: 211-32.

[13]

Taft RJ, Pheasant M, Mattick JS. The relationship between nonproteincoding DNA and eukaryotic complexity. Bioessays. 2007; 29: 288-99.

[14]

Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL, et al. Long noncoding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24: 430-47.

[15]

Mattick JS. Noncoding RNAs: the architects of eukaryotic complexity. EMBO Rep. 2001; 2: 986-91.

[16]

Chen Q, Zeng Y, Kang J, Hu M, Li N, Sun K, et al. Enhancer RNAs in transcriptional regulation: recent insights. Front Cell Dev Biol. 2023; 11: 1205540.

[17]

Aznaourova M, Schmerer N, Schmeck B, Schulte LN. DiseaseCausing Mutations and Rearrangements in Long Noncoding RNA Gene Loci. Front Genet. 2020; 11: 527484.

[18]

Fagny M, Platig J, Kuijjer ML, Lin X, Quackenbush J. Nongenic cancerrisk SNPs affect oncogenes, tumoursuppressor genes, and immune function. Br J Cancer. 2020; 122: 569-77.

[19]

Jin Y, Wang J, Bachtiar M, Chong SS, Lee CGL. Architecture of polymorphisms in the human genome reveals functionally important and positively selected variants in immune response and drug transporter genes. Hum Genomics. 2018; 12: 43.

[20]

Du Z, Sun T, Hacisuleyman E, Fei T, Wang X, Brown M, et al. Integrative analyses reveal a long noncoding RNAsmediated sponge regulatory network in prostate cancer. Nat Commun. 2016; 7: 10982.

[21]

GhafouriFard S, Shoorei H, Anamag FT, Taheri M. The Role of NonCoding RNAs in Controlling Cell Cycle Related Proteins in Cancer Cells. Front Oncol. 2020; 10: 608975.

[22]

Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022; 19: 188-206.

[23]

Zhang L, Yang CS, Varelas X, Monti S. Altered RNA editing in 3’ UTR perturbs microRNAsmediated regulation of oncogenes and tumorsuppressors. Sci Rep. 2016; 6: 23226.

[24]

Pauli A, Rinn JL, Schier AF. Noncoding RNAs as regulators of embryogenesis. Nat Rev Genet. 2011; 12: 136-49.

[25]

Anastasiadou E, Jacob LS, Slack FJ. Noncoding RNA networks in cancer. Nat Rev Cancer. 2018; 18: 5-18.

[26]

Misteli T. The SelfOrganizing Genome: Principles of Genome Architecture and Function. Cell. 2020; 183: 28-45.

[27]

Kauffman SA. Metabolic stability and epigenesis in randomly constructed genetic nets. J Theor Biol. 1969; 22: 437-67.

[28]

Kauffman S. Differentiation of malignant to benign cells. J Theor Biol. 1971; 31: 429-51.

[29]

Huang S, Ernberg I, Kauffman S. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol. 2009; 20: 869-76.

[30]

Huayamares SG, Loughrey D, Kim H, Dahlman JE, Sorscher EJ. Nucleic acidbased drugs for patients with solid tumours. Nat Rev Clin Oncol. 2024; 21: 407-27.

[31]

Poller W, Sahoo S, Hajjar R, Landmesser U, Krichevsky AM. Exploration of the Noncoding Genome for HumanSpecific Therapeutic TargetsRecent Insights at Molecular and Cellular Level. Cells. 2023; 12: 2660.

PDF (1207KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉